NVTA

Invitae Corporation

NVTA

Market cap $25.5M

Overview Fund Activity

Delisted

NVTA was delisted on the 5th of February, 2024.

Back to rankings

About: Invitae Corp operates as a genetic information company in diagnostic and research industry. The company's tests include multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders, metabolic disorders and other hereditary conditions.

Employees: 1,700

Financial journalist opinion

Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare

SAN FRANCISCO , Aug. 14, 2025 /PRNewswire/ -- Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch.

Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare

Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln

Laboratory service provider Labcorp said on Wednesday it will acquire Softbank-backed Invitae Corp's assets auctioned through a voluntary bankruptcy protection process, a few months after the genetic test maker filed for bankruptcy.

Labcorp Announces Winning Bid for Select Assets of Invitae

Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C. , April 24, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.

Labcorp Announces Winning Bid for Select Assets of Invitae

Invitae Enters into Agreement with Labcorp for Sale of Business

– Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO , April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis for $239 million in cash consideration, plus other non-cash consideration.

Invitae Enters into Agreement with Labcorp for Sale of Business

Invitae Publishes its Environmental, Social and Governance (ESG) Report

– Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO , April 22, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year.

Invitae Publishes its Environmental, Social and Governance (ESG) Report

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

– Study findings to be presented at the 2024 American Society of Breast Surgeons Annual Meeting – SAN FRANCISCO , April 11, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced new studies to be presented at the American Society of Breast Surgeons Annual Meeting (ASBrS) held in Orlando from April 10-14, 2024. The featured research will highlight how machine learning can reduce variants of uncertain significance (VUS) in patients who have received genetic testing for breast cancer, in addition to results from real world data showing that uncertain results do not lead to an overuse of mastectomies for breast cancer patients.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification

– An Invitae-developed innovative approach to help reduce variants of uncertain significance – SAN FRANCISCO , March 12, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced the launch of an update to Invitae Generation™ with Clinical Variant Modeling, a novel machine learning approach designed to aid clinical interpretation of genetic testing results and increase the rate of definitive answers for patients. The first of its kind, developed by a multidisciplinary team of computational biologists, machine learning engineers, clinical experts and geneticists, Clinical Variant Modeling methodically leverages clinical information received at the time of testing to improve variant classification and reduce variants of uncertain significance (VUS).

Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results

SAN FRANCISCO , March 6, 2024 /PRNewswire/ -- Invitae (OTC: NVTA), a leading medical genetics company, today announced estimated unaudited fourth quarter and full year 2023 revenue, gross profit and cash burn. Estimated unaudited financial results for fourth quarter 2023 Fourth quarter 2023 revenue was $127.8 million, an increase of approximately 4% from a year ago.

Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

– Announcing Invitae Generation™, a high-quality variant detection and classification platform – SAN FRANCISCO , March 5, 2024 /PRNewswire/ -- Researchers from Invitae (OTC: NVTA), a leading medical genetics company, are showcasing their work next week at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada from March 12-16. The meeting's clinical agenda will include presentations on both research and clinical topics that promote the science and practice of clinical genetics and genomics.

Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting

Genetic test maker Invitae files for bankruptcy protection in US

Softbank-backed genetic test maker Invitae said on Tuesday it has filed for voluntary Chapter 11 protection in a U.S. bankruptcy court and intends to pursue a sale process.

See News Rankings

Charts implemented using Lightweight Charts™